Ketamine - Braxia Scientific
Alternative Names: Ketamine (Intravenous) - Braxia; Ketamine (Oral tablets) - BraxiaLatest Information Update: 28 Nov 2024
Price :
$50 *
At a glance
- Originator Braxia Scientific
- Class Amines; Analgesics; Antidepressants; Antihyperglycaemics; Antiparkinsonians; Anxiolytics; Behavioural disorder therapies; Chlorobenzenes; Cyclohexanes; General anaesthetics; Ketones; Mood stabilisers; Neuroprotectants; Neuropsychotherapeutics; Obesity therapies; Small molecules
- Mechanism of Action AMPA receptor agonists; NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Depressive disorders
Most Recent Events
- 28 Nov 2024 No recent reports of development identified for clinical-Phase-Unknown development in Depressive disorders in Canada (IV)
- 28 Nov 2024 No recent reports of development identified for clinical-Phase-Unknown development in Depressive disorders in Canada (PO, Fast dissolve)
- 29 Aug 2022 Braxia Scientific plans clinical trials in Canada before the end of 2022